Treating moderate to severe atopic dermatitis - NICE TA814
NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
MHRA Drug Safety Update, 26 April 2023
1.1 Abrocitinib and upadacitinib are recommended as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if:
the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable
the companies provide abrocitinib and upadacitinib according to the commercial arrangement.